Drug Profile
Research programme: combination vaccines - Roche
Latest Information Update: 08 Mar 2011
Price :
$50
*
At a glance
- Originator BioVeris Corporation
- Developer Baxter Healthcare Corporation; Roche
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 27 Jun 2007 BioVeris was acquired and merged into Roche
- 31 Jan 2007 BioVeris and Baxter Healthcare entered into a technology license agreement for N. meningitidis group Y and H. influenzae type b components for use in combination vaccines